Eribulin mesylate for the treatment of breast cancer

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49
   PubMed Web of Science ®Google Scholar
• Arriagada R, Spielmann M, Koscielny S, Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen. Ann Oncol 2002;13:1378-86
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer Facts and Figures 2009. Available from: http://www.cancer.org/downloads/STT/F861009_final%209-08-09.pdf [Last accessed 5 May 2010]
   Google Scholar
• Bai RL, Paull KD, Herald CL, Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 1991;266:15882-9
   PubMed Web of Science ®Google Scholar
• Hamel E. Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmacol Ther 1992;55:31-51
   PubMed Web of Science ®Google Scholar
• Towle MJ, Salvato KA, Budrow J, In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001;61:1013-21
   PubMed Web of Science ®Google Scholar
• Sipkema D, Osinga R, Schatton W, Large-scale production of pharmaceuticals by marine sponges: sea, cell, or synthesis? Biotechnol Bioeng 2005;90:201-22
   PubMed Web of Science ®Google Scholar
• Dabydeen DA, Burnett JC, Bai R, Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol 2006;70:1866-75
   PubMed Web of Science ®Google Scholar
• Jordan MA, Kamath K, Manna T, The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005;4:1086-95
   PubMed Web of Science ®Google Scholar
• Kuznetsov G, Towle MJ, Cheng H, Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004;64:5760-6
   PubMed Web of Science ®Google Scholar
• Okouneva T, Azarenko O, Wilson L, Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 2008;7:2003-11
   PubMed Web of Science ®Google Scholar
• Goel S, Mita AC, Mita M, A Phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 2009;15:4207-12
   PubMed Web of Science ®Google Scholar
• Synold TW, Morgan RJ, Newman EM, A Phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: a California Cancer consortium trial [abstract 3036]. J Clin Oncol 2005;23(Suppl):200
   Google Scholar
• Tan AR, Rubin EH, Walton DC, Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 2009;15:4213-19
   PubMed Web of Science ®Google Scholar
• Kuznetsov G, TenDyke K, Yu MJ, Littlefield BA. Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro. [abstract C58]. Proc Am Assoc Cancer Res 2007;48:275
   Google Scholar
• Vahdat L, Twelves C, Allison MAK, Phase II study of eribulin mesylate (E7389) in patients (PTS) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracycline, taxane, and capecitabine therapy [abstract 1084]. J Clin Oncol 2008;26(Suppl):62
   Google Scholar
• Vahdat LT, Pruitt B, Fabian CJ, Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009;27:2954-61
   PubMed Web of Science ®Google Scholar
• Twelves C, Cortes J, Vahdat LT, Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer 2010;10:160-3
   PubMed Web of Science ®Google Scholar
• Perez EA, Lerzo G, Pivot X, Efficacy and safety of ixabepilone (BMS-247550) in a Phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:3407-14
   PubMed Web of Science ®Google Scholar
• Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006;24:1633-42
   PubMed Web of Science ®Google Scholar
• Sparano JA, Wang M, Martino S, Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358:1663-71
   PubMed Web of Science ®Google Scholar
• Rugo HS, Campone M, Amadori D, Pivot. Randomized Phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC) [abstract 1029]. J Clin Oncol 2009;27(Suppl):15
   Google Scholar
• Smith JW II, Vukelja SJ, Rabe AC, Preliminary toxicity results of a Phase II randomized trial of weekly or every 3-week ixabepilone in metastatic breast cancer (MBC) [abstract]. San Antonio Breast Cancer Symposium; 9 – 13 December, 2009. Available from: http://www.abstracts2view.com/sabcs09/view.php?nu=SABCS09L_1129&terms= [Last accessed 5 May 2010]
   Google Scholar
• Goel R, Chen E, Welch S, Phase I study of E7389/gemcitabine combination in patients with advanced solid tumors. J Clin Oncol 2009;27(Suppl): abstract e13509
   PubMed Web of Science ®Google Scholar